Renin Inhibitors: A Novel Approach to HypertensionDecision ResourcesJune 23, 2006 17 Pages - SKU: DECR1305282 |
|
Hypertension, or high blood pressure, is a significant health concern worldwide. It is a major risk factor for cardiovascular disease, and poorly controlled hypertension can damage target organs, eventually resulting in heart failure, end-stage kidney disease, retinopathy, stroke, and vascular dementia. The hypertension therapy market is also one of the largest markets in the world for prescription drugs. In this report, we examine a new class of antihypertensive drug, renin inhibitors. The first of these agents, aliskiren (Novartis/Speedel's Rasilez), is preregistered in the United States. If approved, it will be the first of a new class of antihypertensive drug to enter the market in more than a decade. Please note: the PDF e-mail from publisher version of this report is for a global site license. |
Related Markets
Cardiovascular Reports
- Cardiovascular Partnering Terms and Agreements
- International Stroke Conference 2012 - Post-Conference Review and Analysis
- 6th Asian Pacific Congress of Heart Failure (APCHF) - Post-Conference Review and Analysis
- Arrhythmias Global Clinical Trials Review, H1, 2012
- Unstable Angina Therapeutics - Pipeline Assessment and Market Forecast to 2018
